Orbital Therapeutics chairman John Maraganore (L) and CEO Giuseppe Ciaramella
April 26, 2023 06:00 AM EDTUpdated 09:36 AM
Financing
Startups
Cell/Gene Tx

With $270M, Beam spin­off Or­bital Ther­a­peu­tics builds RNA med­i­cines as it hunts for part­ners, more de­liv­ery tech 

Kyle LaHucik

Senior Reporter

Or­bital Ther­a­peu­tics, the RNA med­i­cines up­start formed by base edit­ing biotech Beam Ther­a­peu­tics, is out with a $270 mil­lion Se­ries A to fu­el work across …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times